Tuesday, November 20, 2012
Genentech Inc., of South San Francisco, a member of the Roche Group, reported results from the Phase III AVAglio study showing that Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy improved progression-free survival by 36 percent vs. radiation and temozolomide plus placebo (p > 0.0001) in patients with newly diagnosed glioblastoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.